VIA-2291

Tallikut Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	VIA-2291
Also known as	atreleuton
Sponsor	Tallikut Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event (PHASE2)
Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy (PHASE2)
Study Effect of VIA-2291 on Vascular Inflammation (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VIA-2291 CI brief — competitive landscape report
VIA-2291 updates RSS · CI watch RSS
Tallikut Pharmaceuticals, Inc. portfolio CI